trending Market Intelligence /marketintelligence/en/news-insights/trending/AbrHaoAp3_0vxiuE1GMB2Q2 content esgSubNav
In This List

Hancock Jaffe completes $2.7M common stock placement

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Hancock Jaffe completes $2.7M common stock placement

Hancock Jaffe Laboratories Inc. completed its private placement of 2,360,051 common shares to investors for gross proceeds of about $2.7 million.

The Irvine, Calif.-based medical device company plans to use the proceeds to develop its two lead products, VenoValve and CoreoGraft, and to fund working capital and general corporate purposes.

VenoValve is used for treating chronic venous insufficiency — a debilitating condition under which veins in a patient's legs are not working effectively. CoreoGraft is used during heart surgeries.